Dr. Eugenia Girda, MD

Dr. Girda practices at Robert Wood Johnson University Hospital in New Brunswick, New Jersey, part of RWJBarnabas Health.

Dr. Girda's NPI, 1497032106, was assigned on November 8, 2011. Dr. Girda graduated from State University of New York at Stony Brook, School of Medicine in 2010. Dr. Girda holds New Jersey license 25MA10141800.

Dr. Girda's primary practice is Robert Wood Johnson University Hospital, at One Robert Wood Johnson Place, New Brunswick, NJ 08901 in Middlesex County. The practice phone is (732) 828-3000. Dr. Girda also practices at Robert Wood Johnson University Hospital - New Brunswick, 1 Robert Wood Johnson Pl, New Brunswick, NJ 08901.

Dr. Girda's primary practice is Robert Wood Johnson University Hospital in New Brunswick, New Jersey, part of RWJBarnabas Health. The medical group on file is Rutgers-RWJ Scleroderma Program. Dmand AI also links Dr. Girda to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Girda practices, 2 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Girda's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dmand AI has Dr. Girda's licenses on file in 2 states: New Jersey and California.

CMS data shows 189 Medicare services from Dr. Girda across 4 procedure codes in 2024, for 86 Medicare patients. Medicare paid $13,844 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 86 Medicare patients who saw Dr. Girda in 2024. The largest group is 65 to 74, with 44 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 17% are also on Medicaid. Their average risk score is 1.77, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Girda's median patient age at 64, with 94% women.

In 2024, Dr. Girda wrote 161 Medicare Part D claims for 51 patients. 78% of them were for generic drugs. CMS names the drug for 71 of them, across 5 drugs with 11 or more claims each, at $156,135 in total drug cost. In 2023, CMS named 41 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Girda for performance year 2024, reported as part of a group. Dr. Girda accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 17 procedures of removal of the uterus by Dr. Girda, more than 90% of the clinicians it reports for that procedure.

Dmand AI links Dr. Girda to 1 clinical trial. 1 is still active or recruiting. Open Payments lists research payments to Dr. Girda that name 1 trial.

CMS Open Payments shows 6 general payments to Dr. Girda from 4 drug and device companies from 2017 to 2024. Consulting fees make up the largest share, 85% of the total. Merck Sharp & Dohme Corporation paid the most, $2,170. It also lists 22 research payments totaling $7,117 from 2022 to 2025, naming 1 clinical trial.

Dr. Girda graduated from State University of New York at Stony Brook, School of Medicine in 2010.